fool.com · 28 jul

United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?

9,500 shares were disposed of for ~$5.0 million based on a weighted average execution price of $530.42 on July 27, 2026. The transaction represents a 1% reduction in total equity holdings, leaving the insider with ~669,000 shares across direct and indirect accounts.

zacks.com · 24 jul

Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?

Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.

defenseworld.net · 24 jul

Atika Capital Management LLC Invests $7.32 Million in United Therapeutics Corporation $UTHR

Atika Capital Management LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ: UTHR) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 12,350 shares of the biotechnology company's stock, valued at approximately $7,323,000. United Therapeutics makes up 0.9% of Atika Capital Management

gurufocus.com · 23 jul

United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Victor Dzau, M.D.,

businesswire.com · 23 jul

United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors

SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Victor Dzau, M.D., to its Board on July 22, 2026.Dr. Dzau recently completed a 12-year tenure as President of the National Academy of Medicine (NAM) and formerly served as Chancellor for Health Affairs at Duke University, President and CEO of the Duke University Health System, and Chairman of Medicine at.

businesswire.com · 22 jul

United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release that will be issued on Wednesday, August 5, 2026, at approximately 6:30 a.m. Eastern Time.United Therapeutics will host a public webcast on Wednesday, August 5, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast of th.

fool.com · 22 jul

PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?

PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.

defenseworld.net · 21 jul

California Public Employees Retirement System Grows Stock Holdings in United Therapeutics Corporation $UTHR

California Public Employees Retirement System increased its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 5.9% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 88,289 shares of the biotechnology company's stock after acquiring an additional